IP Library Granted Patent US 11,357,730
Granted Patent B2
US 11,357,730 · App. 16/235,528 · Granted Jun 14, 2022

Controlled activation ingestible identifier

Inventors: Hooman Hafezi (Redwood City, CA); Timothy Robertson (Belmont, CA); Olivier Colliou (Los Gatos, CA); Mark Zdeblick (Portola Valley, CA)
Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
A61K9/2072A61B5/073A61B5/1473A61B5/14539A61B5/4238A61B5/4833A61B5/4839A61B5/6861A61K49/00H01M10/0436A61B2560/0214A61J3/007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,357,730
App. No.
16/235,528
Granted
Jun 14, 2022
Kind
B2
Abstract

Apparatuses for use with a pharmaceutically acceptable carrier. The apparatus can include a partial power source, which in turn includes electrodes or materials that are configured to generate an electrical potential upon contacting or being exposed to an ionic solution. The apparatus can further include a circuit electrically or communicatively coupled to the partial power source. The circuit can generate various types of signals, such as RF signals, when powered by the partial power source. The circuit is stably fittable to the pharmaceutically acceptable carrier. The apparatus can further include a barrier, a protective layer, or a membrane that isolates the electrodes or materials from the ionic solution and is configured to be dissolved by the ionic solution.

Claims (21)

1. An apparatus for a controlled activation within a patient's body, the apparatus comprising:

a partial power source comprising a first material and a second material, the first material and the second material configured to generate an electrical potential upon contacting an ionic solution;

a circuit electrically coupled to the partial power source, the circuit configured to generate a signal;

a first film covering a first portion of the first material and a first portion of the second material, the first film configured to dissolve under a first condition after being ingested by the patient such that the first portion of the first material and the first portion of the second material activate under the first condition; and

a second film covering a second portion of the first material and a second portion of the second material, the second film configured to dissolve under a second condition after being ingested by the patient such that the second portion of the first material and the second portion of the second material activate under the second condition that occurs after the first condition occurs.

2. The apparatus of claim 1 , wherein the signal comprises an RF signal.

3. The apparatus of claim 1 , wherein the circuit further comprises a coil, the circuit is configured to generate an oscillating current when powered by the partial power source and the coil is configured to generate an RF signal according to the oscillating current.

4. The apparatus of claim 1 , wherein the first film comprises a time-controlled dissolution composition.

5. The apparatus of claim 1 , wherein the first film comprises a composition configured to dissolve upon contacting a solution embodying a target level of a property, the property selected from the group consisting of pH and conductivity.

6. The apparatus of claim 1 , wherein the first film is configured to dissolve at a first pH level, and the second film is configured to dissolve at a second pH level different than the first pH level.

7. The apparatus of claim 1 , wherein the first film is configured to dissolve in a GI tract of the patient and cause the first portion of the first material and the first portion of the second material to activate in the GI tract of the patient, and the second film is configured to dissolve in a stomach area of the patient and cause the second portion of the first material and the second portion of the second material to activate in the stomach area of the patient.

8. The apparatus of claim 1 , wherein either the first film or the second film is configured to dissolve in an intestine area of the patient and cause either the first portion of the first and second materials or the second portion of the first and second materials, respectively, to activate in the intestine area of the patient.

9. The apparatus of claim 1 , wherein the either first film or the second film is configured to dissolve in a colon area of the patient and cause either the first portion of the first and second materials or the second portion of the of the first and second materials, respectively, to activate in the colon area of the patient.

10. The apparatus of claim 1 , wherein the first film is configured to dissolve at a first temperature, and the second film is configured to dissolve at a second temperature different than the first temperature.

11. A method for activating of an apparatus within a patient's body, the method comprising:

dissolving, under a first condition, a first film covering a first portion of a first material and a first portion of a second material, wherein the first and second materials form a partial power source;

generating, via the partial power source, an electrical potential in response to the first and second materials being exposed to a first ionic solution;

generating a first signal via a circuit electrically coupled to the partial power source;

dissolving, under a second condition, a second film covering a second portion of the first material and a second portion of the second material;

generating, via the partial power source, the electrical potential in response to the first and second materials being exposed to a second ionic solution; and

generating a second signal via the circuit electrically coupled to the partial power source.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2021
From: OTSUKA AMERICA PHARMACEUTICAL, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 056239/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2021
From: PROTEUS DIGITAL HEALTH, INC.
To: OTSUKA AMERICA PHARMACEUTICAL, INC.
Reel/Frame 055704/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2019
From: HAFEZI, HOOMAN; ROBERTSON, TIMOTHY; COLLIOU, OLIVIER
To: PROTEUS BIOMEDICAL, INC.
Reel/Frame 048235/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2019
From: ZDEBLICK, MARK
To: PROTEUS DIGITAL HEALTH, INC.
Reel/Frame 048235/0822 →
CHANGE OF NAME Recorded Feb 5, 2019
From: PROTEUS BIOMEDICAL, INC.
To: PROTEUS DIGITAL HEALTH, INC.
Reel/Frame 049855/0168 →
Continuity (4)
Division 14570673 · Dec 15, 2014
Continuation 12447172
Provisional Application 60862925 · Oct 25, 2006
Related Publication 20190133958A1 · May 9, 2019